A Study of ASP1951 in Subjects With Advanced Solid Tumors
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2293965
下载链接
链接失效反馈官方服务：
资源简介：
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1951 when administered as a single agent and in combination with pembrolizumab; and determine the recommended phase 2 dose (RP2D) of ASP1951 and/or maximum tolerated dose (MTD) when administered as a single agent and in combination with pembrolizumab. This study will also evaluate the anti-tumor effect of ASP1951 when administered as a single agent and in combination with pembrolizumab.
创建时间：
2019-01-15
